Article

UROL Test Advertising Article Page

Author(s):

UROL Test Author

UROL Test Advertising Page | Article

 

 

Related Videos
1 expert is featured in this series.
Treatment Decisions in Patients With Low- vs High-Volume Disease
1 expert is featured in this series.
Findings in the Docetaxel-Naive Patient Population
Blur image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com
Endourologist discusses shared decision-making and laser lithotripsy
Shreyas Joshi, MD, recaps AUA session on chemotherapy vs novel NMIBC options
Shreyas Joshi, MD, recaps AUA session on chemotherapy vs novel NMIBC options
Joshua J. Meeks, MD, PhD, answers a question during a Zoom video interview
Joshua J. Meeks, MD, PhD, discusses NIAGARA data for patient undergoing cystectomy
Shay Rajavel, MS3, on CO2 gas embolism during single-port partial nephrectomy
Shay Rajavel, MS3, on CO2 gas embolism during single-port partial nephrectomy
Kevin Zorn, MD, on preserving ejaculation with BPH therapies
Kevin Zorn, MD, on preserving ejaculation with BPH therapies
Neal Shore, MD, on sasanlimab plus BCG for BCG-naïve NMIBC
Neal Shore, MD, on sasanlimab plus BCG for BCG-naïve NMIBC
Alexander Glaser, MD, on real-world outcomes with Aquablation
Alexander Glaser, MD, on real-world outcomes with Aquablation
Vitaly Margulis, MD, on preliminary safety, efficacy of padeliporfin VTP for UTUC
Vitaly Margulis, MD, on preliminary safety, efficacy of padeliporfin VTP for UTUC
Related Content
Conceptual image for prostate cancer treatment, 3D illustration showing destruction of a tumor inside prostate gland | Image Credit: @ Dr_Microbe - stock.adobe.com
May 2nd 2025

Phase 3 trial of capivasertib in mCRPC discontinued following IDMC recommendation

Hannah Clarke
The committee determined that the study was unlikely to meet its dual primary end points of radiographic progression-free survival and overall survival.
Pearls & Perspectives: Evolving role of APPs in urology, with Corinna Hughes, DNP, at AUA 2025
May 1st 2025

Pearls & Perspectives: Evolving role of APPs in urology, with Corinna Hughes, DNP, at AUA 2025

Amy M. Pearlman, MD
Corinna Hughes, DNP, sits down with Amy Pearlman, MD, to discuss the evolving recognition of APPs in urology.
Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
May 1st 2025

Safety, efficacy of vibegron sustained in men with OAB treated for BPH

Benjamin P. Saylor
The investigators reported an overall incidence of AEs of 29.6%.
Pearls & Perspectives: Future of reconstructive urology, with Ryan Terlecki, MD, at AUA 2025
April 30th 2025

Pearls & Perspectives: Future of reconstructive urology, with Ryan Terlecki, MD, at AUA 2025

Amy M. Pearlman, MD Ryan Terlecki, MD
A discussion on evolution of surgical education, importance of video training, and the future of patient-centered care in reconstruction.
TAR-200 boasts impressive DFS rates in papillary disease-only NMIBC
April 30th 2025

TAR-200 boasts impressive DFS rates in papillary disease-only NMIBC

Hannah Clarke
Data showed a disease-free survival rate of 85.3% at 6 months and 81.1% at 9 months.
Man talking with a doctor | Image Credit: © Pcess609 - stock.adobe.com
Published: April 29th 2025 | Updated: April 29th 2025

Ultra-low PSA responses are more prevalent with darolutamide plus ADT

Benjamin P. Saylor
The investigators reported that ultra-low PSA responses “were associated with prolonged rPFS and delayed progression to mCRPC and PSA progression.”
© 2025 MJH Life Sciences

All rights reserved.